Please assess the completion status of the following clinical trial:

Trial Title: Ferinject® Assessment In GastRectomy Patients With Acute Isovolemic Anemia (FAIRY)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 20 years old~* 7g/dl ≤ Hb \< 10g/dl at 5 - 7 days after gastrectomy for gastric cancer~* signed written informed consent~Exclusion Criteria:~* a concurrent medical condition(s) that would prevent compliance or participation or jeopardize the health of the patient~* hypersensitivity to any component of the formulation~* active severe infection/inflammation~* History of transfusion, erythropoietin, \> 500 mg intravenous iron administration within 4 weeks prior to screening.~* History of acquired iron overload.~* Pregnancy or lactation.~* Decreased renal function (defined as creatinine clearance \< 50 mL/min calculated by Cockcroft-Gault)~* Chronic liver disease or increase of liver enzymes (ALT, AST) \> 3 times the upper limit of normal range.~* Participation in any other interventional study within 1 month prior to screening.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferinject® Group (Type: EXPERIMENTAL): Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with 7g/dl≤Hb\<10g/dl at 5 - 7 days after gastrectomy for gastric cancer.
- Placebo Group (Type: PLACEBO_COMPARATOR): Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with 7g/dl≤Hb\<10g/dl at 5 - 7 days after gastrectomy for gastric cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).